Top Mid Cap Stocks To Add to Your Watchlist - April 7th

Key Points

• MarketBeat's screener names seven Mid Cap stocks to watch: ProShares UltraPro Short QQQ (SQQQ), Terns Pharmaceuticals (TERN), Direxion Daily TSLA Bull 2X (TSLL), Avis Budget Group (CAR), Applied Optoelectronics (AAOI), Booking Holdings (BKNG), and Soleno Therapeutics (SLNO), each ranking among the highest in recent dollar trading volume.
• The selections span diverse themes — including a 3x inverse Nasdaq ETF (SQQQ), leveraged equity exposure (TSLL), clinical-stage biotechs (TERN, SLNO), travel and rental plays (BKNG, CAR), and fiber‑optic tech (AAOI) — offering a mix of growth potential and tactical hedging opportunities.
• Mid-cap context: Mid-cap stocks (roughly $2B–$10B market caps) are highlighted as a middle ground between small- and large-cap equities, typically providing moderate risk/return and useful portfolio diversification.

ProShares UltraPro Short QQQ, Terns Pharmaceuticals, Direxion Daily TSLA Bull 2X Shares, Avis Budget Group, Applied Optoelectronics, Booking, and Soleno Therapeutics are the seven Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with a market capitalization generally between about $2 billion and $10 billion, though specific cutoffs vary by index provider. To investors, mid-caps represent a middle ground between small- and large-cap stocks, offering a blend of growth potential and relative stability—typically carrying moderate risk and return and serving as a diversification tool in portfolios. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Read Our Latest Research Report on TERN

Direxion Daily TSLA Bull 2X Shares (TSLL)

Read Our Latest Research Report on TSLL

Avis Budget Group (CAR)

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the following segments: Americas, International, and Corporate and Other. The Americas segment includes the vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean.

Read Our Latest Research Report on CAR

Applied Optoelectronics (AAOI)

Applied Optoelectronics, Inc. designs, manufactures, and sells fiber-optic networking products in the United States, Taiwan, and China. It offers optical modules, optical filters, lasers, laser components, subassemblies, transmitters and transceivers, turn-key equipment, headend, node, distribution equipment, and amplifiers.

Read Our Latest Research Report on AAOI

Booking (BKNG)

Booking Holdings Inc, formerly The Priceline Group Inc., is a provider of travel and restaurant online reservation and related services. The Company, through its online travel companies (OTCs), connects consumers wishing to make travel reservations with providers of travel services across the world. It offers consumers an array of accommodation reservations (including hotels, bed and breakfasts, hostels, apartments, vacation rentals and other properties) through its Booking.com, priceline.com and agoda.com brands.

Read Our Latest Research Report on BKNG

Soleno Therapeutics (SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

Read Our Latest Research Report on SLNO

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.